Attached files

file filename
EX-31.2 - EX-31.2 - Editas Medicine, Inc.ex-31d2.htm
EX-31.1 - EX-31.1 - Editas Medicine, Inc.ex-31d1.htm
EX-10.2 - EX-10.2 - Editas Medicine, Inc.ex-10d2.htm
EX-10.1 - EX-10.1 - Editas Medicine, Inc.ex-10d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10‑Q/A

Amendment No. 1


(Mark One)

☒   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

OR

☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ________

Commission File Number 001‑37687


EDITAS MEDICINE, INC.

(Exact name of registrant as specified in its charter)


 

 

 

Delaware

 

46‑4097528

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)

 

 

 

11 Hurley Street

 

 

Cambridge, Massachusetts

 

02141

(Address of principal executive offices)

 

(Zip Code)

 

(617) 401‑9000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S‑T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

 

Large accelerated filer       ☐

 

Accelerated filer                   ☒

 

 

 

Non‑accelerated filer        ☐

(Do not check if a smaller reporting company)

Smaller reporting company  ☐

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                   ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐   No ☒

 

The number of shares of the Common Stock outstanding as of August 3, 2018 was 47,675,644.

 

 

 

 


 

EXPLANATORY NOTE

This Form 10‑Q/A constitutes Amendment No. 1 to the Quarterly Report on Form 10‑Q of Editas Medicine, Inc. for the period ended June 30, 2018, originally filed with the Securities and Exchange Commission (“SEC”) on August 7, 2018 (the “Original Filing”). We are filing this Amendment No. 1 to our Quarterly Report on Form 10‑Q solely to provide revised copies of Exhibits 10.1 and 10.2 that were included with the Original Filing, reflecting revisions made in response to SEC comments in connection with our confidential treatment request. In accordance with Rule 12b‑15 under the Securities Exchange Act of 1934, as amended, Item 6 is amended to reflect the filing of revised Exhibits 10.1 and 10.2, and to include new certifications as Exhibit 31.1 and Exhibit 31.2.

This Amendment No. 1 does not change any other portion of the Original Filing. This Amendment No. 1 speaks as of the original filing date of the Original Filing and does not reflect events occurring after the filing date of the Original Filing, or modify or update the disclosures therein in any way other than as required to reflect the amendment described above. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing and our other filings with the SEC.


 

Item 6.   Exhibits

Exhibit Index

 

 

 

Exhibit
Number

    

Description of Exhibit

10.1

 

Amended and Restated License and Collaboration Agreement, dated May 3, 2018, between the Registrant and Juno Therapeutics, Inc. 

10.2

 

Sponsored Research Agreement, dated June 7, 2018, between the Registrant and The Broad Institute, Inc.

31.1

 

Rule 13a‑14(a) Certification of Principal Executive Officer

31.2

 

Rule 13a‑14(a) Certification of Principal Financial Officer

101.INS+

 

XBRL Instance Document

101.SCH+

 

XBRL Taxonomy Extension Schema Document

101.CAL+

 

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF+

 

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB+

 

XBRL Taxonomy Extension Label Linkbase Document

101.PRE+

 

XBRL Taxonomy Extension Presentation Linkbase Document

 


†      Confidential treatment has been requested as to certain portions, which portions in each case have been omitted and separately filed with the SEC.

+      Previously filed with the Registrant’s Quarterly Report on Form 10‑Q for the quarter ended June 30, 2018, filed with the SEC on August 7, 2018, which is being amended hereby.


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

EDITAS MEDICINE, INC.

 

 

 

 

 

 

Dated: October 23, 2018

By:

/s/ Andrew A. F. Hack

 

 

 

Andrew A. F. Hack M.D., Ph.D.

 

 

Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)